Testing small, frequent drug doses for children whose brain tumor came back
Original title: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage test in people, not care you can get from your own doctor yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing small, frequent doses of cancer drugs for children whose brain tumor came back or grew.
Who this trial is for. It is mostly for children whose medulloblastoma, ependymoma, ATRT, or another rare brain tumor came back or kept growing. It tests small, frequent doses of cancer drugs given with other medicines, aimed at blocking the growth of blood vessels.
Where it stands. The team is checking how many people's tumors shrink, stay the same, or do not come back after 6 months. They are also looking at side effects, quality of life, and how long people live. In one medulloblastoma group, people are placed by chance into one of two drug mixes so the two can be compared. One earlier part of the trial has finished, but its results are not given here. The parts still going on have not reported results.
What this means, and what it doesn't
What it could mean: The goal is to help people live longer while keeping a good quality of life. Small doses given often are meant to cause fewer side effects than standard doses. One part of the trial also includes some adults. If this sounds like your situation, you could ask your care team about it.
What it doesn't mean: This is a test, not a proven treatment. Joining does not mean it will help you or your child. It is not a cure. Whether someone can join is decided by the trial team, not by us.
Source: ClinicalTrials.gov, September 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.